Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318916 | 0.96 | SCN9A (0.53) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690594 | 0.94 | SCN9A (0.50) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL322578 | 0.93 | SCN9A (0.48) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL10147883 | 0.90 | SCN9A (0.52) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690625 | 0.87 | SCN9A (0.47) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL322805 | 0.85 | SCN9A (0.43) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690576 | 0.84 | SCN9A (0.56) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL10185797 | 0.80 | SCN9A (0.42) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1093817 | 0.80 | SCN9A (0.62) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690643 | 0.79 | SCN9A (0.54) | SCN9ACYP2C9SCN1ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | SCN9A 12/4885CYP2C9 533/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.